|1.||Toutain, Pierre-Louis: 6 articles (01/2015 - 07/2003)|
|2.||Lees, P: 5 articles (01/2013 - 06/2002)|
|3.||Bousquet-Mélou, Alain: 4 articles (01/2015 - 08/2009)|
|4.||Ferran, Aude A: 4 articles (01/2015 - 08/2009)|
|5.||Schneider, M: 3 articles (12/2014 - 07/2002)|
|6.||Sidhu, P K: 3 articles (05/2010 - 02/2006)|
|7.||Landoni, M F: 3 articles (05/2010 - 02/2006)|
|8.||Waxman, S: 3 articles (02/2004 - 07/2002)|
|9.||San Andrés, M I: 3 articles (02/2004 - 07/2002)|
|10.||González, F: 3 articles (02/2004 - 07/2002)|
07/01/2002 - "Marbofloxacin is a fluoroquinolone antibiotic expected to be effective in the treatment of infections involving gram-negative and some gram-positive bacteria in horses. "
08/01/2013 - "These data suggest that RIVLP of marbofloxacin (0.67 mg/kg) could be a safe and effective method for treatment of infections of the distal portion of the limb for susceptible organisms."
10/31/2006 - "The purpose of this study was to investigate the effect of chronic feline immunodeficiency virus (FIV) infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection. "
03/01/2006 - "The purpose of this study was to investigate the effect of chronic feline immunodeficiency virus (FIV) infection, and efficacy of marbofloxacin treatment, on 'Candidatus Mycoplasma haemominutum' infection. "
12/01/2006 - "aureus) to determine the clinical efficacy of marbofloxacin in the treatment of this infection. "
06/01/2001 - "Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study."
06/01/2001 - "The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. "
06/01/1999 - "Thirty-nine dogs with severe and/or recurrent lesions of pyoderma were treated with marbofloxacin at an average dosage of 2.12 mg/kg bodyweight, once daily, for time periods varing from 10 to 213 days. "
06/01/1999 - "Therapy of difficult cases of canine pyoderma with marbofloxacin: a report of 39 dogs."
06/01/2001 - "Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial."
03/01/2015 - "Evaluating synergy between marbofloxacin and gentamicin in Pseudomonas aeruginosa strains isolated from dogs with otitis externa."
02/11/2006 - "Twenty dogs with otitis externa in both ears and numerous Malassezia species yeasts on cytological examination were treated in one ear with a combination product containing clotrimazole, marbofloxacin and dexamethasone, and in the other ear with a topical antifungal containing miconazole. "
01/01/2012 - "Chlorhexidine and Tris-EDTA in combination with marbofloxacin/dexamethasone/clotrimazole were effective in cytological reduction of bacteria in canine infectious otitis externa. "
|4.||Renal Insufficiency (Renal Failure)
12/01/1998 - "The clearance of marbofloxacin was slightly decreased after the induction of renal failure (1.6+/-0.2 to 1.4+/-0.1 mL/kg/min) (P < 0.05), but no significant variation of volume of distribution at steady state (Vss) and mean residence time (MRT) was observed after intravenous administration of marbofloxacin (P > 0.05). "
12/01/1998 - "Following oral administration of marbofloxacin, an increase in total area under the concentration time curve (AUC) was observed after renal failure (from 10372+/-1710 to 11459+/-1119 mg x min/L) (P < 0.05), but indices of accumulation were not modified. "
|3.||Edetic Acid (EDTA)
|7.||Biological Markers (Surrogate Marker)